Sugi Predict

Sugi Predict / Compounds / SCHEMBL3546145

SCHEMBL3546145

SCHEMBL3546145

O=C(O)c1ccc(O)c(O)c1Cl

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SELL P14151 1/20 0.64
▸ SELP P16109 1/20 0.64
▸ CA1 P00915 4/20 0.52
▸ CA2 P00918 4/20 0.52
▸ TSHR P16473 4/20 0.48
▸ MEN1 O00255 3/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ KDR P35968 2/20 0.45
▸ PDE4A P27815 1/20 0.45
▸ BLVRB P30043 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ ALDH1A1 P00352 6/20 0.45
▸ CA12 O43570 3/20 0.45
▸ CA7 P43166 3/20 0.45
▸ CA9 Q16790 3/20 0.45
▸ CA14 Q9ULX7 3/20 0.45
▸ PTGS2 P35354 2/20 0.45
▸ ALOX5 P09917 1/20 0.45
▸ CYP1A2 P05177 1/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18529852 0.86 SELL (0.56) SELLSELPCA1CA2TSHR
SCHEMBL28842145 0.84 SELL (0.48) SELLSELPCA1CA2MEN1
SCHEMBL529328 0.84 SELL (0.54) SELLSELPCA1CA2TSHR
SCHEMBL29941520 0.82 SELL (0.64) SELLSELPCA1CA2TSHR
SCHEMBL4069345 0.82 DPP4 (0.56) SELLSELPCA1CA2TSHR
SCHEMBL2649879 0.82 SELL (0.64) SELLSELPCA1CA2TSHR
SCHEMBL15680143 0.81 SELL (0.42) SELLSELPCA1CA2TSHR
SCHEMBL29556588 0.81 SELL (0.42) SELLSELPCA1CA2TSHR
SCHEMBL31346680 0.80 SELL (0.45) SELLSELPCA1CA2MEN1
SCHEMBL3218306 0.80 SELL (0.45) SELLSELPCA1CA2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118063409-A Preparation method of cefdinir and intermediate thereof 江苏美迪克化学品有限公司 2024-05-24 — — CN claimed
CN-118063409-A Preparation method of cefdinir and intermediate thereof 江苏美迪克化学品有限公司 2024-05-24 — — CN disclosed
CN-118063409-A Preparation method of cefdinir and intermediate thereof 江苏美迪克化学品有限公司 2024-05-24 — — CN disclosed
US-10933051-B2 Carbapenem compounds and compositions for the treatment of bacterial infections FOB SYNTHESIS, INC. (US) 2021-03-02 — — US disclosed
US-10933051-B2 Carbapenem compounds and compositions for the treatment of bacterial infections FOB SYNTHESIS, INC. (US) 2021-03-02 — — US disclosed
US-20200155508-A1 Carbapenem Compounds and Compositions for the Treatment of Bacterial Infections CHOI, WOO-BAEG, DR. 2020-05-21 — — US disclosed
US-20200155508-A1 Carbapenem Compounds and Compositions for the Treatment of Bacterial Infections CHOI, WOO-BAEG, DR. 2020-05-21 — — US disclosed
EP-3634471-A1 CARBAPENEM COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS FOB Synthesis, Inc. (US) 2020-04-15 — — EP disclosed
CN-106132954-B 1,3- benzodioxole derivative 第三共株式会社 2019-01-08 — — CN disclosed
WO-2018227178-A1 CARBAPENEM COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS FOB SYNTHESIS, INC. (US) 2018-12-13 — — WO disclosed
EP-2341053-A1 CEPHALOSPORIN HAVING CATECHOL GROUP Shionogi & Co., Ltd. (JP) 2011-07-06 — — EP disclosed
US-7741479-B2 Urea inhibitors of MAP kinases LOCUS PHARMACEUTICALS, INC. (US) 2010-06-22 — — US disclosed
EP-1828169-A2 UREA INHIBITORS OF MAP KINASES Locus Pharmaceuticals, Inc. (US) 2007-09-05 — — EP disclosed
US-20060167247-A1 Urea inhibitors of MAP kinases LOCUS PHARMACEUTICALS, INC. 2006-07-27 — — US disclosed
WO-2006062982-A2 UREA INHIBITORS OF MAP KINASES LOCUS PHARMACEUTICALS, INC. (US) 2006-06-15 — — WO disclosed
EP-0416410-B1 Piperaziniocephalosporins SHIONOGI & CO (JP) 1994-11-30 — — EP disclosed
US-5143910-A PIPERAZINIOCEPHALOSPORINS SHIONOGI & CO., LTD. (JP) 1992-09-01 — — US disclosed
EP-0416410-A1 Piperaziniocephalosporins SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) 1991-03-13 — — EP disclosed
US-4865648-A ELECTRON DONOR DYE; ESTER; PHENOL, CARBOXY ACID, PHOSPHATE ESTER, TRIAZOLE KITO TSUTOMU (JP) 1989-09-12 — — US disclosed
US-4720301-A Reversible heat sensitive recording composition PILOT INK CO., LTD. (JP) 1988-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10933051-B2 Carbapenem compounds and compositions for the treatment of bacterial infections SLC11A2, GSK3B, GSK3A SELL 4241/4885SELP 2626/4885CA1 2804/4885
US-20200155508-A1 Carbapenem Compounds and Compositions for the Treatment of Bacterial Infections SLC11A2, GSK3B, GSK3A SELL 4241/4885SELP 2626/4885CA1 2804/4885
US-20060167247-A1 Urea inhibitors of MAP kinases MAPK1, MAP3K1, MAP3K20 SELL 3869/4885SELP 2600/4885CA1 3862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.